Payment overview · 2025
General Payments
$62,655.76
88 reported records · 11 companies
Healthcare provider profile · identity verified
Karolinne Maia Rocha, MD, PHD
Allopathic & Osteopathic Physicians|Ophthalmology · CHARLESTON, SC · NPI 1699098053
Verified facts
What the public records show
CMS Open Payments records show Karolinne Maia Rocha, MD, PHD received $62,655.76 in general payments during 2025 across 88 reported records.
Johnson & Johnson Surgical Vision, Inc. accounted for 43.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Cequa, Miebo, Xiidra.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOTEMAX as an associated drug or biological on 10 records involving 10 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Lotemax by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOTEMAX SM as an associated drug or biological on 92 records involving 67 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Lotemax Sm by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MIEBO as an associated drug or biological on 34133 records involving 12967 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Miebo by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIIDRA as an associated drug or biological on 28163 records involving 11019 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Xiidra by this doctor in 2024.
SUN PHARMACEUTICAL INDUSTRIES INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Cequa as an associated drug or biological on 25765 records involving 9461 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Cequa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | Unresolved — no canonical attribution shown | $27,429.92 | 43.8% | 22 | 2025 |
| Bausch & Lomb Americas Inc. | Unresolved — no canonical attribution shown | $22,851.00 | 36.5% | 31 | 2025 |
| Tarsus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $4,601.23 | 7.3% | 9 | 2025 |
| Carl Zeiss Meditec, Inc. | Unresolved — no canonical attribution shown | $1,700.00 | 2.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $1,620.71 | 2.6% | 8 | 2025 |
| Glaukos Corporation | Unresolved — no canonical attribution shown | $1,460.15 | 2.3% | 2 | 2025 |
| Alcon Vision LLC | Unresolved — no canonical attribution shown | $1,256.62 | 2.0% | 5 | 2025 |
| Alcon Research LLC | Unresolved — no canonical attribution shown | $1,055.53 | 1.7% | 2 | 2025 |
| Harrow Eye, LLC | Unresolved — no canonical attribution shown | $367.29 | 0.6% | 4 | 2025 |
| BIOTISSUE HOLDINGS INC. | Unresolved — no canonical attribution shown | $226.75 | 0.4% | 2 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $86.56 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $57,436.25 | 20 |
| Food and Beverage | $3,610.46 | 60 |
| Travel and Lodging | $1,609.05 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Compact Intuitiv Normalized: compact intuitiv |
Device | Johnson & Johnson Surgical Vision, Inc. | $24,806.25 | 7 | 2025 |
Source payment records
|
|||||
| IFS ADVANCED FEMTOSEC LASER Normalized: ifs advanced femtosec laser |
Device | Johnson & Johnson Surgical Vision, Inc. | $24,806.25 | 7 | 2025 |
Source payment records
|
|||||
| enVista MX60 IOL Normalized: envista mx60 iol |
Device | Bausch & Lomb Americas Inc. | $8,599.74 | 4 | 2025 |
Source payment records
|
|||||
| IC-8 Apthera IOL Normalized: ic 8 apthera iol |
Device | Bausch & Lomb Americas Inc. | $1,874.09 | 4 | 2025 |
Source payment records
|
|||||
| KXL System Normalized: kxl system |
Device | Glaukos Corporation | $1,275.00 | 1 | 2025 |
Source payment records
|
|||||
| TRYPTYR Normalized: tryptyr |
Drug | Alcon Vision LLC | $1,127.91 | 3 | 2025 |
Source payment records
|
|||||
| CALLISTO eye Normalized: callisto eye |
Device | Carl Zeiss Meditec, Inc. | $1,020.00 | 1 | 2025 |
Source payment records
|
|||||
| CIRRUS HD-OCT Normalized: cirrus hd oct |
Device | Carl Zeiss Meditec, Inc. | $1,020.00 | 1 | 2025 |
Source payment records
|
|||||
| IOLMaster 700 Normalized: iolmaster 700 |
Device | Carl Zeiss Meditec, Inc. | $1,020.00 | 1 | 2025 |
Source payment records
|
|||||
| MEL 90 Normalized: mel 90 |
Device | Carl Zeiss Meditec, Inc. | $1,020.00 | 1 | 2025 |
Source payment records
|
|||||
| VisuMax Normalized: visumax |
Device | Carl Zeiss Meditec, Inc. | $1,020.00 | 1 | 2025 |
Source payment records
|
|||||
| TECNIS IOL Normalized: tecnis iol |
Device | Johnson & Johnson Surgical Vision, Inc. | $977.27 | 7 | 2025 |
Source payment records
|
|||||
| ELITA Normalized: elita |
Device | Johnson & Johnson Surgical Vision, Inc. | $872.01 | 6 | 2025 |
Source payment records
|
|||||
| VERITAS Vision System Normalized: veritas vision system |
Device | Johnson & Johnson Surgical Vision, Inc. | $872.01 | 6 | 2025 |
Source payment records
|
|||||
| CATALYS SYSTEM Normalized: catalys system |
Device | Johnson & Johnson Surgical Vision, Inc. | $463.69 | 7 | 2025 |
Source payment records
|
|||||
| VEVYE Normalized: vevye |
Drug | Harrow Eye, LLC | $367.29 | 4 | 2025 |
Source payment records
|
|||||
| LUMIGAN Normalized: lumigan |
Drug | ABBVIE INC. | $275.92 | 4 | 2025 |
Source payment records
|
|||||
| MIEBO Normalized: miebo |
Drug | Bausch & Lomb Americas Inc. | $187.35 | 9 | 2025 |
Source payment records
|
|||||
| Photrexa Viscous and Photrexa Normalized: photrexa viscous and photrexa |
Drug | Glaukos Corporation | $185.15 | 1 | 2025 |
Source payment records
|
|||||
| Tecnis Simplicity Normalized: tecnis simplicity |
Device | Johnson & Johnson Surgical Vision, Inc. | $182.71 | 2 | 2025 |
Source payment records
|
|||||
| XDEMVY Normalized: xdemvy |
Drug | Tarsus Pharmaceuticals, Inc. | $136.95 | 5 | 2025 |
Source payment records
|
|||||
| AcrySof IQ PanOptix UV IOL Normalized: acrysof iq panoptix uv iol |
Device | Alcon Vision LLC | $104.15 | 1 | 2025 |
Source payment records
|
|||||
| Cequa Normalized: cequa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $86.56 | 1 | 2025 |
Source payment records
|
|||||
| XIIDRA Normalized: xiidra |
Drug | Bausch & Lomb Americas Inc. | $47.41 | 6 | 2025 |
Source payment records
|
|||||
| NGENUITY Normalized: ngenuity |
Device | Alcon Vision LLC | $24.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Cequa cequa |
2025 | Cequa | 2024 | 34 | exact normalized | Medicare Part D |
| MIEBO miebo |
2025 | Miebo | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIIDRA xiidra |
2025 | Xiidra | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | LOTEMAX open payments reported associated product |
CMS Open Payments — General Payments 10 supporting records · 10 recipient NPIs · example record 1254762767 |
Lotemax · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | LOTEMAX SM open payments reported associated product |
CMS Open Payments — General Payments 92 supporting records · 67 recipient NPIs · example record 1254732081 |
Lotemax Sm · 2024 Exact normalized brand match · 1 Part D row |
22 | 13 |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | MIEBO open payments reported associated product |
CMS Open Payments — General Payments 34133 supporting records · 12967 recipient NPIs · example record 1254730224 |
Miebo · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | XIIDRA open payments reported associated product |
CMS Open Payments — General Payments 28163 supporting records · 11019 recipient NPIs · example record 1254730224 |
Xiidra · 2024 Exact normalized brand match · 1 Part D row |
48 | 16 |
| SUN PHARMACEUTICAL INDUSTRIES INC. Exact reporting entity; no affiliate inference |
2025 | Cequa open payments reported associated product |
CMS Open Payments — General Payments 25765 supporting records · 9461 recipient NPIs · example record 1250962431 |
Cequa · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisolone Acetate | Prednisolone Acetate | 208 | 112 |
| Cyclosporine | Cyclosporine | 109 | 52 |
| Restasis | Cyclosporine | 92 | 37 |
| Latanoprost | Latanoprost | 79 | 28 |
| Valacyclovir | Valacyclovir Hcl | 61 | 17 |
| Timolol Maleate | Timolol Maleate | 57 | 16 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 54 | 20 |
| Moxifloxacin | Moxifloxacin Hcl | 54 | 36 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 25 |
| Xiidra | Lifitegrast | 48 | 16 |
| Restasis Multidose | Cyclosporine | 45 | 13 |
| Erythromycin | Erythromycin Base | 38 | 20 |
| Cequa | Cyclosporine | 34 | 12 |
| Lotemax | Loteprednol Etabonate | 28 | suppressed |
| Lotemax Sm | Loteprednol Etabonate | 22 | 13 |
| Fluorometholone | Fluorometholone | 20 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 18 | 17 |
| Miebo | Perfluorohexyloctane/Pf | 16 | suppressed |
| Loteprednol Etabonate | Loteprednol Etabonate | 14 | suppressed |
| Ofloxacin | Ofloxacin | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $62,655.76 · 88 records | Johnson & Johnson Surgical Vision, Inc. | AcrySof IQ PanOptix UV IOL, CALLISTO eye, CATALYS SYSTEM, CIRRUS HD-OCT, Cequa, Compact Intuitiv, ELITA, IC-8 Apthera IOL, IFS ADVANCED FEMTOSEC LASER, IOLMaster 700, KXL System, LUMIGAN, MEL 90, MIEBO, NGENUITY, Photrexa Viscous and Photrexa, TECNIS IOL, TRYPTYR, Tecnis Simplicity, VERITAS Vision System, VEVYE, VisuMax, XDEMVY, XIIDRA, enVista MX60 IOL | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Cequa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bausch & Lomb Americas Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error